Transaction · 0002109299-26-000009

Bhalla Narinder Pal

Bhalla Narinder Pal, CMO, reported a transaction classified as grant at Lexeo Therapeutics, Inc. involving 54750.000000 shares for an estimated $0.00. Reported holdings after the transaction were 54750.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACMO
LXEOLexeo Therapeutics, Inc.
Filing timeSep 28
Trade dateSep 24, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position tradedUnavailableNot calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$4.18
Pre-filing
1mo ago +21.3%1w ago +0.0%1d ago +0.0%
Returns since
7d30d90d180d1y

LXEO price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
LXEO since 2026-09-28Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0002109299-26-000009
Stock Option (right to buy)
Transaction date
Sep 24, 2026
Filed Sep 28, 2026, 09:15 PM · 4d delay
Shares
54.7k sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
54.7k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
-10score
Filing-only score

-10

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exe…

  2. F2

    Includes 49,500 Restricted Stock Units.

  3. F3

    25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the…

Original filing · 0002109299-26-000009
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

LXEO